Descriptive analysis of PD-L1 expression in non-small cell lung carcinoma biopsies: two -year experience in a tertiary Hospital
DOI:
https://doi.org/10.32932/gecp.2021.07.014Keywords:
PD -L1, non-small cell carcinoma, lungAbstract
Introduction: The expression of PD-L1 as a predictive marker of response to treatment of non-small cell lung cancer (NSCLC) allows the identification of patients most likely to benefit from treatment with inhibitors of immune checkpoints. The main objective of this study was to determine the PD-L1 positivity/negativity rates of biopsies diagnosed with NSCLC during the year 2017 and 2018 at CHUPorto and compare with the predicted rates.Materials and methods: All biopsies of lung, bronchus or pleura diagnosed with primary epithelial neoplasia were surveyed and categorized according to the age and sex of patients, the reported diagnosis, the level of expression of PD-L1 and the mutational study.
Results: Of the 262 cases identified, 57% were diagnosed with adenocarcinoma, 26% with squamous cell carcinoma, 11% with neuroendocrine neoplasia and 6% with others. PD-L1 expression was evaluated in 215 biopsies out of 229 recorded with the diagnosis of NSCLC. Of these 215 cases, 54% were negative, 26% showed mild to intermediate positivity and 20% high positivity for PD-L1.
Discussion and conclusion: The evaluation of PD-L1 expression in lung cancer biopsies is an essential tool for defining the treatment of these patients. The values of PD-L1 expression described here in the clinical practice of CHUPorto tend to be more negative than those described in the original clinical trial, but similar to those described by real-life studies. Given the impact that the expression of PD-L1 has on the management of patients with NSCLC in daily clinical practice, it is important to know our reality. As future perspectives, we consider important the correlation analysis of PD-L1 expression with the results of treatment with inhibitors of immune checkpoints.
Downloads
References
Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018, 379(24):2342-50.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018, 378(22):2078-92.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell LungCancer. N Engl J Med. 2016, 375(19):1823-33.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lungcancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016, 387(10027):1540-50.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomized controlled trial. Lancet. 2017, 389(10066):255-65.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015, 373(17):1627-39.
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Committee. Ann Oncol. 2018, 29(Suppl 4):192-237
PD-L1 IHC 22C3 pharmDx Interpretation Manual – NSCLC. Agilent DAKO
Munari E, Zamboni G, Marconi M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget. 2017, 8(52):90123-31
Roach C, Zhang N, Corigliano E, et al. Development of a Companion Diagnostic PD-L1 Immunohisto-chemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. Appl Immunohisto-chem Mol Morphol. 2016, 24(6):392-7
Marchetti A, Barberis M, Franco R, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NS-CLC Patients to Be Treated with Immune Checkpoint Inhibitors. J Thorac Oncol. 2017, 12(11):1654-63
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 2015. International Agency for Research on Cancer, Lyon, France 13. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019, 30(8):1321-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.